Pfizer (PFE)
(Delayed Data from NYSE)
$28.09 USD
-0.21 (-0.74%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.09 USD
-0.21 (-0.74%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
Pfizer (PFE) Gets Approval for New Eczema Drug in Europe
by Zacks Equity Research
Pfizer's (PFE) oral JAK inhibitor, Cibinqo, gets approval for treating atopic dermatitis in adults who are candidates for systemic therapy in Europe.
Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.
J&J's (JNJ) COVID-19 Booster Jab Gets WHO Recommendation
by Zacks Equity Research
An advisory group of the World Health Organization recommends the booster dose of J&J's (JNJ) COVID-19 vaccine for use in adults.
Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod
by Kinjel Shah
Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.
ETFs to Play the Reopening Trade as Omicron Fear Subsides
by Sweta Jaiswal, FRM
The improved market sentiments have been leading to greater attention and confidence in reopening trades.
Pfizer (PFE) COVID-19 Booster Gives Protection Against Omicron
by Zacks Equity Research
Pfizer (PFE) and BioNTech announce lab test data that demonstrates that the three doses of their COVID-19 vaccine provide significant protection against the Omicron variant.
Stock Market News for Dec 9, 2021
by Zacks Equity Research
U.S. stocks closed slightly higher on Wednesday, with major indexes hovering around their record highs, as reports suggested that the Omicron variant of the coronavirus looks less dangerous that it was earlier thought.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $51.40 in the latest trading session, marking a -0.62% move from the prior day.
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
by Zacks Equity Research
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for USMC
AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study
by Zacks Equity Research
AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.
Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study
by Zacks Equity Research
Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.
Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
J&J (JNJ) COVID-19 Booster Jab Compares Well With Comirnaty
by Zacks Equity Research
Booster dose of J&J's (JNJ) COVID-19 vaccine elicits comparable neutralizing activity and higher T-cell responses in previously-vaccinated persons with Comirnaty.
AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label
by Zacks Equity Research
AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron
by Kinjel Shah
The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
Pfizer (PFE) Up 22% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review
by Zacks Equity Research
Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.
Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote
by Zacks Equity Research
An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.
Moderna's (MRNA) Stock Falls on Omicron Variant Concerns
by Zacks Equity Research
Moderna (MRNA) shares decline following a two-day rise as the Omicron-variant creates uncertainty with limited data. The next couple of weeks may provide a clearer picture.
The Zacks Analyst Blog Highlights: Mastercard, Pfizer, Nike, Lockheed Martin and Micron Tech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, Pfizer, Nike, Lockheed Martin and Micron Tech